Immediate-Release Solid Dosage Form With Embedded Drug Microstructures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid dosage forms face inefficiencies in manufacturing processes, leading to batch-to-batch variations, high costs, and unsuitable drug release profiles, particularly for immediate drug release applications, due to complex granule compaction and incomplete understanding of particulate behavior.
Innovation Solution
The development of solid dosage forms produced via solidification of a fluid, featuring drug-containing structural elements such as thin sheets, fibers, or particles embedded in a nondrug-containing matrix, allowing for predictable and flexible drug release properties through a cost-effective, deterministic manufacturing process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If granule compaction is used to manufacture solid dosage forms, then mechanical strength and structural integrity are achieved, but batch-to-batch variations and manufacturing complexity increase
Solution Approach 1:
The invention changes the physical state parameter of the material from solid granules to liquid melt during processing. The melt-extruded dosage form is formed from a liquid state and then solidified, fundamentally changing the processing parameters from mechanical compression to thermal processing. This eliminates the variability associated with granule compaction while maintaining structural integrity through controlled solidification.
Solution Approach 2:
The invention replaces the mechanical compaction system with a thermal processing system. Instead of using mechanical force to compress granules into tablets, the invention uses heat to melt the material, extrude it in liquid form, and then allows controlled solidification. This substitution eliminates the mechanical variability inherent in granule compaction processes.
2Ease of operation
If multiple downstream unit operations are used in powder processing, then desired flowability and compressibility properties are achieved, but process time and manufacturing cost increase
Solution Approach 1:
The invention merges multiple downstream unit operations (blending, granulating, drying, milling, screening, tableting, coating) into a single integrated melt-extrusion process. The liquid melt state allows all these operations to be performed simultaneously or in sequence within one continuous process, dramatically reducing process time while achieving the desired properties.
Solution Approach 2:
By changing the material state to liquid melt, the invention eliminates the need for separate operations to achieve flowability and compressibility. The liquid state inherently provides excellent flowability for molding, and the controlled solidification provides the desired structural properties, consolidating multiple process steps into one.
3Stability of the object's composition
If cast solid dosage forms with non-porous matrices are used, then chemical stability is improved, but drug release rate decreases
Solution Approach 1:
The invention introduces a porous or cellular microstructure into the solid dosage form through controlled gas bubble incorporation during the melt-extrusion process. This porous structure allows gastrointestinal fluid to penetrate rapidly into the interior while maintaining the chemically stable polymeric matrix, thus achieving both fast drug release and chemical stability.
Solution Approach 2:
The invention creates a composite structure combining a chemically stable polymeric matrix with a porous cellular architecture. The polymeric matrix provides chemical stability, while the porous structure facilitates rapid fluid penetration and drug release. This composite approach resolves the contradiction between stability and release rate.
4Manufacturing precision
If extensive powder preparation is performed, then desired dosage form properties are achieved, but manufacturing complexity and capital cost increase
Solution Approach 1:
The invention replaces extensive mechanical powder preparation equipment with a single melt-extrusion system. The thermal processing approach eliminates the need for complex mechanical equipment used in blending, granulating, drying, milling, and tableting, significantly reducing device complexity while maintaining or improving dosage form properties.
Solution Approach 2:
By changing from solid-state mechanical processing to liquid-state thermal processing, the invention simplifies the manufacturing equipment required. The melt-extrusion process uses temperature and pressure parameters instead of mechanical force, requiring fewer and simpler equipment components while achieving consistent dosage form properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new dosage forms achieve rapid drug dissolution and consistent drug release within 45 minutes with minimal batch-to-batch variation, enhancing manufacturing efficiency and reducing production time and costs.
Implementation Method 1
heating and melting the polymer and the drug in a melt extruder
Implementation Method 2
The mixture is then pressed through a die and cooled or dried to solidify the mixture
Data Source
Figure 1A~2B
Figure 3A~3B
Figure 4
AI summary
A solid pharmaceutical dosage form includes a drug-containing solid and a nondrug-containing matrix. The drug-containing solid includes one or more drug- containing structural elements that are embedded in or attached to the nondrug- containing matrix. The drug-containing structural elements include one of zero- dimensional elements, one-dimensional elements, two-dimensional elements, or combinations thereof. The drug-containing structural elements are a solidified liquid or paste. The pharmaceutical dosage form has a size greater than an average thickness of the one or more drug-containing structural elements.